[1] 国家药典委员会.中华人民共和国药典临床用药须知.化学药和生物制品卷(2015年版).中国医药科技出版社, 2015: 303- 310.
[2] 陈新谦, 金有豫, 汤光, 主编. 新编药物学(第17版). 人民卫生出版社, 2011: 418- 420.
[3] Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ,2008,178:576-584.
[4] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版). 中华健康管理学杂志, 2017, 11: 7-28.
[5] 胡大一. 2010调脂治疗领域进展. 中国新药杂志, 2011, 20: 1358- 1361.
[6] Jeon CY, Goodman MT, Cook-wiens G, et al. Statin use and survival with eady-stage hepatocellular carcinoma. Callcer Epidemiol Biomarkers Prev, 2016, 25: 686- 692.
[7] Eslami L, Merat S, Malekzdeh R, et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochmne Database Syst Rev, 2013, 27: 197-203.
[8] Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf, 2008, 31: 325-334.
[9] Huang YE, Lee CL, Yang SS, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: A nationwide cohort study. Liver, Am J Gastroenterol, 2016, 111: 976–985.
[10] Simon TG, Bonilla H, Yan P, et al. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology, 2016,64: 47-57.
[11] Onofrei MD, Butler KL, Fuke DC, et al. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy,2008, 28: 522-529.
[12] Graf H, Jungst C, Straub G, et al, ChemoeIIlbolization coIIlbined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion, 2008, 78: 34-48.
[13] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版).胃肠病学和肝病学杂志, 2010,19: 483- 487.
[14] 鲁跃华, 周传堃, 陈爱武, 等. 氟伐他汀和辛伐他汀调脂疗效、不良反应及价-效关系比较研究. 中华心血管病杂志, 2002, 30: 673-674.
[15] 方任飞, 李静湖, 张杰, 等. 基于处方序列对称分析的他汀类药物肝脏安全性研究.中华流行病学杂志, 2016, 37: 935-939.
[16] 他汀类药物安全性评价工作组. 他汀类药物安全性评价专家共识. 中华心血管病杂志, 2014,: 890-894.
[17] Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med, 2015, 372: 1500-1509. |
